(Q53180872)

English

Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease.

scientific article published in December 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

Vedolizumab and Infliximab Combination Therapy in the Treatment of Crohn's Disease. (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

Brian P Bosworth

3

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

author name string

Robert Hirten

1

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

Randy S Longman

2

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

Adam Steinlauf

4

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

Ellen Scherl

5

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

language of work or name

0 references

publication date

1 December 2015

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

The American Journal of Gastroenterology

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

110

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

12

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

1737-1738

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26673509

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26673509

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab, azathioprine, or combination therapy for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26673509

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed

1 reference

https://pubmed.ncbi.nlm.nih.gov/26673509

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab.

1 reference

https://pubmed.ncbi.nlm.nih.gov/26673509

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vedolizumab as induction and maintenance therapy for Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/26673509

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/AJG.2015.355

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 May 2018

http://europepmc.org/abstract/MED/26673509

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53180872&oldid=1449378773"